Principal Financial Group Inc. Grows Stock Position in Elanco Animal Health Incorporated $ELAN

Principal Financial Group Inc. raised its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 7.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,386,907 shares of the company’s stock after acquiring an additional 94,671 shares during the quarter. Principal Financial Group Inc.’s holdings in Elanco Animal Health were worth $33,189,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. UBS Group AG lifted its position in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after purchasing an additional 5,961,457 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Elanco Animal Health by 11.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after purchasing an additional 3,717,404 shares in the last quarter. Invesco Ltd. increased its stake in Elanco Animal Health by 336.0% during the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after buying an additional 3,690,735 shares during the period. Artemis Investment Management LLP purchased a new stake in Elanco Animal Health during the 4th quarter worth $55,693,000. Finally, Goldman Sachs Group Inc. lifted its holdings in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 0.0%

NYSE ELAN opened at $25.84 on Monday. The company has a market capitalization of $12.91 billion, a price-to-earnings ratio of -51.68, a price-to-earnings-growth ratio of 1.69 and a beta of 1.68. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. Elanco Animal Health Incorporated has a 12 month low of $13.39 and a 12 month high of $27.72. The company’s fifty day moving average price is $23.63 and its two-hundred day moving average price is $23.90.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company’s revenue was up 14.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ELAN shares. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Citigroup lifted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. TD Cowen increased their price target on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Finally, Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $28.55.

Insider Activity

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. This represents a 2.98% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rajeev A. Modi bought 4,911 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $20.35 per share, with a total value of $99,938.85. Following the transaction, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.14% of the stock is owned by insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.